Integrating antibodies against EpCAM, HER2, and EGFR in CTC isolation platforms improved capture rates and provided a more comprehensive profile of CTC populations in breast and non-small cell lung cancer patients [28,95,96]. The gene discussed is EPCAM; the disease is non-small cell lung carcinoma.